Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
|Videos|September 25, 2020
Gender disparity seen with renal cell carcinoma management
Author(s)Urology Times staff
Meredith R. Metcalf, MD, discusses recent research evaluating management of clinical T1a RCC in men and women.
Advertisement
In this interview, Meredith R. Metcalf, MD, discusses a paper published in Urology titled "Gender Differences in the Clinical Management of Renal Cell Carcinoma," for which she served as a study author. Metcalf is instructor of urology at Johns Hopkins University, Baltimore.
Advertisement
Related to this article
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5